Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. DRUG DEVELOPMENT PARTNERSHIP AND LICENSE AGREEMENT FOR CUDC-906 AND CUDC-908Drug Development Partnership and License Agreement • May 10th, 2012 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS DRUG DEVELOPMENT PARTNERSHIP AND LICENSE AGREEMENT (the “Agreement”) is entered into as of February 24, 2012 (the “Effective Date”) by and between CURIS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 4 Maguire Road, Lexington, MA 02421, USA (“Curis”), and GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO, LTD., a company organized under the laws of the People’s Republic of China, having its principal offices at Room C209, Sector C, Guangzhou International Business Incubator, 3 Juquan Road, Guangzhou Science Park, Guangdong 510663, People’s Republic of China (“GBMT”).
